Cart
sales@molnova.com
ZEN-3694
CAS No. 1643947-30-1
ZEN-3694( —— )
Catalog No. M34476 CAS No. 1643947-30-1
ZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 93 | Get Quote |
|
| 5MG | 140 | Get Quote |
|
| 10MG | 227 | Get Quote |
|
| 25MG | 403 | Get Quote |
|
| 50MG | 642 | Get Quote |
|
| 100MG | 888 | Get Quote |
|
| 500MG | 1782 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameZEN-3694
-
NoteResearch use only, not for human use.
-
Brief DescriptionZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.
-
DescriptionBET-IN-19 (Compound 146) is a BET inhibitor. BET-IN-19 inhibits hlL-6 mRNA transcription (IC50 ≤ 0.3 uM), and c-myc activity in human AML MV4-11 cell (IC50 ≤ 0.3 uM)。BET-IN-19 inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC50 ≤ 0.3 uM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1643947-30-1
-
Formula Weight333.39
-
Molecular FormulaC19H19N5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(N1C=2C(N=C1NC)=NC=C(C2)C=3C(C)=NOC3C)C4=CC=CC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bryan Cordell DUFFY, et al. Novel bicyclic bromodomain inhibitors. Patent. WO2015002754 A2.
molnova catalog
related products
-
FHD-286
FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.
-
Alobresib
Alobresib is an inhibitor of BET bromodomain,is an antineoplastic drug candidate.
-
3-methyl-1,2-dihydro...
3-methyl-1,2-dihydroquinolin-2-one is the first known micromolar inhibitors of the ATAD2 bromodomain.
